{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:17:54Z","timestamp":1774689474010,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s41030-025-00287-1","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:20:31Z","timestamp":1743265231000},"page":"235-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elexacaftor\/Tezacaftor\/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7959-1548","authenticated-orcid":false,"given":"Hans Kristian","family":"R\u00e5ket","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel Z\u00f6llner","family":"Ankarfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Jimenez-Solem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Bj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the TransformCF Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Leo-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bryrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger Hee Mabuza","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine H\u00f8jte","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esben Herborg","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terese","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibi Uhre","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlen Stade Bader","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majbritt","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen Jimenez","family":"Solem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"287_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","author":"PR Burgel","year":"2024","unstructured":"Burgel PR, Southern KW, Addy C, Battezzati A, Berry C, Bouchara JP, et al. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros. 2024. https:\/\/doi.org\/10.1056\/NEJMoa1908639.","journal-title":"J Cyst Fibros"},{"issue":"19","key":"287_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"287_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265\u201371.","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"287_CR4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138.","journal-title":"Lancet"},{"issue":"9","key":"287_CR5","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ppul.25535","volume":"56","author":"T Thorat","year":"2021","unstructured":"Thorat T, McGarry LJ, Bonafede MM, Limone BL, Rubin JL, Jariwala-Parikh K, et al. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatr Pulmonol. 2021;56(9):2833\u201344.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"287_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1183\/09031936.00224911","volume":"41","author":"JM Bradley","year":"2013","unstructured":"Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41(3):571\u20137.","journal-title":"Eur Respir J"},{"issue":"5","key":"287_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ppul.25251","volume":"56","author":"RC Perkins","year":"2021","unstructured":"Perkins RC, Shah M, Sawicki GS. An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatr Pulmonol. 2021;56(5):928\u201338.","journal-title":"Pediatr Pulmonol"},{"key":"287_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13375","author":"T Qvist","year":"2024","unstructured":"Qvist T, Nielsen BU, Olesen HV, Mathiesen IHM, Faurholt-Jepsen D, Katzenstein TL, et al. Close monitoring and early intervention: management principles for cystic fibrosis in Denmark. APMIS. 2024. https:\/\/doi.org\/10.1111\/apm.13375.","journal-title":"APMIS"},{"key":"287_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, Heijerman HGM, Heijerman HGM., McKone EF, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8.","journal-title":"Lancet"},{"key":"287_CR10","doi-asserted-by":"crossref","unstructured":"O\u2019Shea KM, O\u2019Shea KM, O\u2019Carroll O, O\u2019Carroll O, Carroll C, Carroll C, et al. The efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced lung disease. Eur Respir J. 2020;","DOI":"10.1183\/13993003.03079-2020"},{"issue":"4","key":"287_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A, et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J Cyst Fibros. 2023;22(4):730\u20137.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"287_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1377\/hlthaff.2017.1554","volume":"37","author":"LB Feng","year":"2018","unstructured":"Feng LB, Grosse SD, Green RF, Fink AK, Sawicki GS. Precision medicine in action: the impact of ivacaftor on cystic fibrosis-related hospitalizations. Health Aff. 2018;37(5):773\u20139.","journal-title":"Health Aff"},{"key":"287_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundb\u00f8ll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563\u201391.","journal-title":"Clin Epidemiol"},{"key":"287_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/CLEP.S41905","volume":"5","author":"B Vest-Hansen","year":"2013","unstructured":"Vest-Hansen B, Riis AH, Christiansen CF. Registration of acute medical hospital admissions in the Danish National Patient Registry: a validation study. Clin Epidemiol. 2013;5:129\u201333.","journal-title":"Clin Epidemiol"},{"key":"287_CR15","unstructured":"Statens Serum Institut. Covid-19 timeline, 2020\u20132022 [Danish] [Internet]. [cited 2024 Aug 8]. Available from: https:\/\/www.ssi.dk\/-\/media\/arkiv\/subsites\/covid19\/presse\/tidslinje-over-covid-19\/covid-19-tidslinje-lang-for-2020-2022-version-2---december-2022.pdf"},{"key":"287_CR16","unstructured":"Statistics Denmark. Documentation of statistics for The Population 2024 [Internet]. [cited 2024 Aug 5]. Available from: https:\/\/www.dst.dk\/Site\/Dst\/SingleFiles\/GetArchiveFile.aspx?fi=697853694402&fo=0&ext=kvaldel"},{"key":"287_CR17","unstructured":"Statistics Denmark. Documentation of statistics for Health Insurance Statistics 2023 [Internet]. [cited 2024 Aug 5]. Available from: https:\/\/www.dst.dk\/Site\/Dst\/SingleFiles\/GetArchiveFile.aspx?fi=205843697377&fo=0&ext=kvaldel"},{"issue":"3","key":"287_CR18","first-page":"798","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798\u2013798f.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"287_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41030-023-00241-z","volume":"9","author":"MS Schechter","year":"2023","unstructured":"Schechter MS, Sabater-Anaya N, Oster G, Weycker D, Wu H, Arteaga-Solis E, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare resource utilization and associated costs among people with cystic fibrosis in the US: a retrospective claims analysis. Pulm Ther. 2023;9(4):479\u201398.","journal-title":"Pulm Ther"},{"issue":"1","key":"287_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","volume":"23","author":"KW Southern","year":"2024","unstructured":"Southern KW, Addy C, Bell SC, Bevan A, Borawska U, Brown C, et al. Standards for the care of people with cystic fibrosis; establishing and maintaining health. J Cyst Fibros. 2024;23(1):12\u201328.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"287_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","volume":"75","author":"AC Miller","year":"2022","unstructured":"Miller AC, Harris LM, Cavanaugh JE, Abou Alaiwa M, Stoltz DA, Hornick DB, et al. The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor-ivacaftor. Clin Infect Dis. 2022;75(7):1115\u201322.","journal-title":"Clin Infect Dis"},{"key":"287_CR22","doi-asserted-by":"crossref","unstructured":"De Vuyst R, Kam CW, McKinzie CJ, Esther CR. Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor. Pediatr Pulmonol. 2024;","DOI":"10.22541\/au.171228099.99627720\/v1"},{"issue":"6","key":"287_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","volume":"21","author":"JT Song","year":"2022","unstructured":"Song JT, Desai S, Franciosi AN, Dagenais RVE, Quon BS. Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis. J Cyst Fibros. 2022;21(6):1080\u20131.","journal-title":"J Cyst Fibros"},{"issue":"24","key":"287_CR24","first-page":"01813","volume":"S1569\u20131993","author":"HK R\u00e5ket","year":"2024","unstructured":"R\u00e5ket HK, Jensen CB, Wang JN, Pressler T, Olesen HV, Skov M, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study. J Cyst Fibros. 2024;S1569\u20131993(24):01813\u20137.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"287_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/ppul.27051","volume":"59","author":"H Nay\u0131r B\u00fcy\u00fck\u015fahin","year":"2024","unstructured":"Nay\u0131r B\u00fcy\u00fck\u015fahin H, Emiralio\u011flu N, Yal\u00e7\u0131n E, \u015een V, Selimo\u011flu \u015een H, Arslan H, et al. Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators. Pediatr Pulmonol. 2024;59(10):2499\u2013506.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"287_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jcf.2018.11.010","volume":"18","author":"IL Hollin","year":"2019","unstructured":"Hollin IL, Donaldson SH, Roman C, Aliaj E, Riva D, Boyle M, et al. Beyond the expected: identifying broad research priorities of researchers and the cystic fibrosis community. J Cyst Fibros. 2019;18(3):375\u20137.","journal-title":"J Cyst Fibros"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:26:54Z","timestamp":1747999614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00287-1","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tavs Qvist discloses receiving compensation from Vertex Pharmaceuticals for lectures, presentations, speaking engagements, manuscript authorship, and educational events during the years 2021\u20132025, unrelated to the current work. S\u00f8ren Jensen-Fangel declares receiving payment from GSK for delivering a lecture on pulmonary infections in immunocompromised hosts, unrelated to the submitted work, and serving on a Takeda advisory board in 2023, also outside submitted work. Vertex Pharmaceuticals funded this study and provided feedback on the manuscript prior to submission but did not influence the choice of study design, analysis, or interpretation of data. The final decisions regarding study methodology, data presentation, and manuscript content were made by the investigators. All other authors, including Hans Kristian R\u00e5ket, Mikkel Z\u00f6llner Ankarfeldt, Joanna Nan Wang, Tacjana Pressler, Daniel Faurholt-Jepsen, Espen Jimenez-Solem, Janne Petersen, and Camilla Bj\u00f8rn Jensen, report no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The project was approved by the Danish Data Protection Agency (ref. no. P-2020\u20131130). Data were stored in the DCFR with the individuals\u2019 informed, written consent. We thank the individuals for their consent. All data were pseudonymized and accessed with permission from Statistics Denmark (project number FCVH708303). Ethical approval from the Danish Health Research Ethics Committee is not required for registry-based studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}